ADAG Adagene Inc

Price (delayed)

$3.58

Market cap

$169.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.38

Enterprise value

$101.38M

?
Relative Growth: Rel. Growth: 38
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 62

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic ...

Highlights
The debt has dropped by 66% year-on-year
ADAG's EPS is up by 49% year-on-year
ADAG's equity is down by 30% year-on-year

Key stats

What are the main financial stats of ADAG

ADAG stock price

How has the Adagene stock price performed over time
Intraday
7.83%
1 week
0%
1 month
-5.54%
1 year
80.81%
YTD
89.42%
QTD
-8.67%

Financial performance

How have Adagene's revenue and profit performed over time
Revenue
$7.67M
Gross profit
$7.67M
Operating income
$37.1M
Net income
-$17.61M
Gross margin
100%
Net margin
-229.6%
The net margin has surged by 99% year-on-year
The operating margin has plunged by 99% YoY
ADAG's net income is up by 47% year-on-year

Price vs fundamentals

How does ADAG's price correlate with its fundamentals

Growth

What is Adagene's growth rate over time

Valuation

What is Adagene stock price valuation
P/E
N/A
P/B
4.77
P/S
22.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.22
ADAG's EPS is up by 49% year-on-year
ADAG's equity is down by 30% year-on-year

Efficiency

How efficient is Adagene business performance
ADAG's return on sales has surged by 99% year-on-year
The ROA rose by 36% YoY
The ROE has grown by 26% YoY

Dividends

What is ADAG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADAG.

Financial health

How did Adagene financials performed over time
The total assets is 197% more than the total liabilities
The quick ratio is up by 33% year-on-year
The company's current ratio rose by 33% YoY
The debt is 82% smaller than the equity
The debt has dropped by 66% year-on-year
Adagene's debt to equity has plunged by 51% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.